Literature DB >> 11052270

Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients.

R L Madden1, J G Mulhern, B J Benedetto, M H O'Shea, M J Germain, G L Braden, J O'Shaughnessy, G S Lipkowitz.   

Abstract

Although acute rejection (AR) has been shown to correlate with decreased long-term renal allograft survival, we have noted AR in recipients who subsequently had stable function for more than 5 years. We reviewed 109 renal graft recipients with a minimum of 1 year graft survival and follow-up of 5-8 years. Post-transplant sodium iothalamate clearances (IoCI) measured at 3 months and yearly thereafter were used to separate recipients into 2 groups. In 61 patients (stable group), there was no significant decrease ( > 20 % reduction in IoCl over 2 consecutive years) in IoCl. Forty-eight patients had significant declines in IoCl (decline group). Groups were compared for incidence, severity, timing, and completeness of reversal of AR. Rejection was considered completely reversed if the post-AR serum creatinine (Scr) returned to or below the pre-AR nadir Scr after anti-rejection therapy. The incidence of AR was not significantly different between groups (47% vs 52%). A trend toward a lower mean number of AR episodes per patient was noted in the stable group (0.69 vs 1.04, P = 0.096), but the timing of AR was not different. Steroid-resistant AR occurred in approximately 25 % of both groups. A striking difference was seen in complete reversal of AR, with the stable group having 100% (42/42 episodes of AR in 29 patients) complete reversal whereas only 32 % (8/25) of the patients in the decline group had complete reversal (P < < 0.001). Of 8 declining patients with complete reversal, graft loss was due to chronic rejection (CR) in only 3. Seventeen declining patients had incomplete reversal of AR, and 82 % (14/17) lost their grafts to CR. Overall, only 8% (3/37) of the recipients with complete reversal of AR developed CR. No patients with incompletely reversed AR had stable long-term function as measured by IoCl. AR is not invariably deleterious to long-term renal graft function if each episode of AR can be completely reversed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052270     DOI: 10.1007/s001470050712

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

Review 1.  [Kidney transplant pathology].

Authors:  K Amann; M Büttner; K Benz; H Schöcklmann
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

2.  Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study.

Authors:  S Gourishankar; R Leduc; J Connett; J M Cecka; F Cosio; A Fieberg; R Gaston; P Halloran; L Hunsicker; B Kasiske; D Rush; J Grande; R Mannon; A Matas
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

3.  Capillary deposition of complement C4d and C3d in Chinese renal allograft biopsies.

Authors:  Rong Lv; Wei Zhang; Fei Han; Guangjun Liu; Wenqing Xie; Jianghua Chen
Journal:  Dis Markers       Date:  2015-03-04       Impact factor: 3.434

Review 4.  Efficacy of Acute Cellular Rejection Treatment According to Banff Score in Kidney Transplant Recipients: A Systematic Review.

Authors:  Caroline Lamarche; Jean-Maxime Côté; Lynne Sénécal; Héloïse Cardinal
Journal:  Transplant Direct       Date:  2016-11-15

5.  A Three-Year Experience With Overseas Kidney Transplantation in a Tertiary Transplant Center in Saudi Arabia.

Authors:  Mohammed Tawhari; Mansoor Radwi
Journal:  Cureus       Date:  2022-04-09

6.  How Should Acute T-cell Mediated Rejection of Kidney Transplants Be Treated: Importance of Follow-up Biopsy.

Authors:  Fahad Aziz; Sandesh Parajuli; Neetika Garg; Maha Mohamed; Weixiong Zhong; Arjang Djamali; Didier Mandelbrot
Journal:  Transplant Direct       Date:  2022-03-25

7.  Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies.

Authors:  Somratai Vadcharavivad; Warangkana Saengram; Annop Phupradit; Nalinee Poolsup; Wiwat Chancharoenthana
Journal:  Drugs       Date:  2019-12       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.